hotspot -WSS

hotspot

author：fashion 2025-08-26 01:32:38 - browse：23

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Why Sanofi got shellacked over its spinoff

WSS

Telehealth options flood the market as retailers push virtual care

First Opinion Podcast: How to protect health care in times of war

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Physician subsidies by hospitals soar in wake of No Surprises Act

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Hospitals warn Medicare's drug payment fix is ‘unlawful’

focus

hotspot

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

The FDA weighs the risks of candy

As demand for Covid shots wanes, Moderna seeks its next success

Paying for Covid pills will soon shift to insurers

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: XBI biotech index, Akero Therapeutics

Heart attack and stroke risk calculators need revising

Cytokinetics CEO stresses company can launch heart drug on its own

How one medical school became remarkably diverse

Addiction experts warn against a second 'war on drugs'

hotspot

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Arc Institute generative AI designs new CRISPR systems

Readers respond to H5N1 and livestock movements, and more

Senate panel to vote on hospitals, PBMs, prisoner care

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Emergency medicine has repudiated 'excited delirium.' Now what?

focus

knowledge

knowledge

focus